RAC Committee Raises Issues With Nucleonics' HBV Trial; Firm Says IND Timeline Unchanged

/Home/Biologics Delivery - Protein Synthesis/RNA - Protein Synthesis/RNAi - Protein Synthesis

RAC Committee Raises Issues With Nucleonics' HBV Trial; Firm Says IND Timeline Unchanged
December 21, 2006
By Doug Macron
RNAi News
Earlier this month, the NIH?s Recombinant DNA Advisory Committee raised a number of concerns with how Nucleonics designed its proposed phase I trial for its hepatitis B drug, including the size of the doses it plans to evaluate, and the company?s decision to study the drug in only one type of mouse model in its preclinical research.
Subscription is required to view article.